CoChat

Genome editing of HBG1 and HBG2 to induce fetal hemoglobin

Open access

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Abstract

Key Points: Cas9 editing of the γ-globin gene promoters in hematopoietic stem cells (HSCs) increases red cell HbF by ≤40%. No deleterious effects on hematopoiesis or off-target mutations were detected 16 weeks after xenotransplantation of edited HSCs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2019000820

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Cas9:sgRNA RNP disruption of a transcriptional repressor binding motif in the g -globin gene promoters. (A) The extended b -globin locus, showing the target BCL11A binding motif in the promoters of the genes encoding g -globin ( HBG2 and HBG1 ). The 13-nt HPFH deletion is indicated by a dashed black line. sgRNA-1 target is represented by a black line, with a vertical arrow indicating the predicted site of Cas9 dsDNA cleavage and the protospacer adjacent motif (PAM) sequence indicated in gray. (B) Optimization of the Cas9:sgRNA-1 ratio on indel formation, using the Neon Transfection System. RNPs were generated by incubating the indicated amounts of Cas9 and sgRNA in 5 m L of 10 mM HEPES, 150 mM NaCl for 30 min at room temperature. Here and in subsequent experiments, sgRNA-1 was chemically modified to enhance stability. The RNPs were mixed with 2 3 10 5 CD34 1 cells in T buffer in a final volume of 10 m L, electroporated using a Neon Transfection System at 1600 V, with 3 pulses of 10 ms, cultured for 4 days, and then analyzed for indel formation by high-throughput sequencing of PCR products generated using primers located ; 150 bp on either side of the RNP cleavage site. The graphs show the mean 6 standard deviation (SD) indel frequency on the y-axis (n 5 3 biological replicates). Dark blue indicates the 13-nt human HPFH mutation; light blue represents all other indels. (C) Sequence alignment of the most common mutant alleles. The sgRNA-1 sequence is underlined and bolded, the PAM sequence is in red, and the BCL11A-binding motif is highlighted in blue. Deletions are represented by dashes. The percentage of each mutation observed is shown on the right, with the NGS read counts in parentheses. LCR, locus control region.
Figure 1 Cas9:sgRNA RNP disruption of a transcriptional repressor binding motif in the g -globin gene promoters. (A) The extended b -globin locus, showing the target BCL11A binding motif in the promoters of the genes encoding g -globin ( HBG2 and HBG1 ). The 13-nt HPFH deletion is indicated by a dashed black line. sgRNA-1 target is represented by a black line, with a vertical arrow indicating the predicted site of Cas9 dsDNA cleavage and the protospacer adjacent motif (PAM) sequence indicated in gray. (B) Optimization of the Cas9:sgRNA-1 ratio on indel formation, using the Neon Transfection System. RNPs were generated by incubating the indicated amounts of Cas9 and sgRNA in 5 m L of 10 mM HEPES, 150 mM NaCl for 30 min at room temperature. Here and in subsequent experiments, sgRNA-1 was chemically modified to enhance stability. The RNPs were mixed with 2 3 10 5 CD34 1 cells in T buffer in a final volume of 10 m L, electroporated using a Neon Transfection System at 1600 V, with 3 pulses of 10 ms, cultured for 4 days, and then analyzed for indel formation by high-throughput sequencing of PCR products generated using primers located ; 150 bp on either side of the RNP cleavage site. The graphs show the mean 6 standard deviation (SD) indel frequency on the y-axis (n 5 3 biological replicates). Dark blue indicates the 13-nt human HPFH mutation; light blue represents all other indels. (C) Sequence alignment of the most common mutant alleles. The sgRNA-1 sequence is underlined and bolded, the PAM sequence is in red, and the BCL11A-binding motif is highlighted in blue. Deletions are represented by dashes. The percentage of each mutation observed is shown on the right, with the NGS read counts in parentheses. LCR, locus control region.CC-BY-NC-ND · From the PDF
Figure 2 Gene editing induces HbF expression in cultured erythroid cells. G-CSF -mobilized CD34 1 cells were edited with Cas9:sgRNA-1 RNP using the Neon Transfection System (supplemental Methods). They were then grown in culture for 21 days under conditions that support erythroid differentiation. Data show studies from 2 different CD34 1 cell donors (blue or red), with each dot representing separate experiments. (A) Indel frequencies in gene-edited (RNP) and control (C) groups determined 4 days after editing. Dark blue indicates the 13-nt human HPFH mutation; light blue represents all other indels. (B) Cells immunostaining for hemoglobin F (F-cells) measured by flow cytometry at culture day 21. (C) The %HbF in day 21 erythroid cell lysates determined by ion-exchange high-performance liquid chromatography (HPLC). The bar charts in panels A-C show the results as the mean 6 SD. **** P , .0001 (unpaired Student t test). (D) Erythroid maturation kinetics at culture days 7, 14, and 21, as determined by immunoflow cytometry measurement of CD49d and Band3 expression on CD235a 1 erythroid cells. (E) Enucleated cell fractions at culture days 14, 17, and 21, as determined by flow cytometry for CD235a and the cell-permeable DNA dye Hoechst 333412. The numbers in each quadrant show the mean percentages 6 SDs. The data reflect studies of CD34 1 cells from 2 different donors in 7 independent experiments.
Figure 2 Gene editing induces HbF expression in cultured erythroid cells. G-CSF -mobilized CD34 1 cells were edited with Cas9:sgRNA-1 RNP using the Neon Transfection System (supplemental Methods). They were then grown in culture for 21 days under conditions that support erythroid differentiation. Data show studies from 2 different CD34 1 cell donors (blue or red), with each dot representing separate experiments. (A) Indel frequencies in gene-edited (RNP) and control (C) groups determined 4 days after editing. Dark blue indicates the 13-nt human HPFH mutation; light blue represents all other indels. (B) Cells immunostaining for hemoglobin F (F-cells) measured by flow cytometry at culture day 21. (C) The %HbF in day 21 erythroid cell lysates determined by ion-exchange high-performance liquid chromatography (HPLC). The bar charts in panels A-C show the results as the mean 6 SD. **** P , .0001 (unpaired Student t test). (D) Erythroid maturation kinetics at culture days 7, 14, and 21, as determined by immunoflow cytometry measurement of CD49d and Band3 expression on CD235a 1 erythroid cells. (E) Enucleated cell fractions at culture days 14, 17, and 21, as determined by flow cytometry for CD235a and the cell-permeable DNA dye Hoechst 333412. The numbers in each quadrant show the mean percentages 6 SDs. The data reflect studies of CD34 1 cells from 2 different donors in 7 independent experiments.CC-BY-NC-ND · From the PDF
Figure 3 Xenotransplantation of normal gene-edited CD34 1 cells into NBSGW mice. Peripheral blood (PB) CD34 1 cells were edited with Cas9:sgRNA-1 RNP using the Neon Transfection System and then transplanted into NBSGW mice via tail-vein injection. Donor cell controls (C) were processed in parallel, but not electroporated. Donor-cell progeny were analyzed in recipient peripheral blood at 6, 11, and 16 weeks and in bone marrow (BM) at 17 weeks after transplantation. Data are from 3 independent experiments with CD34 1 cells from different donors (red, blue, or green). Each dot in graphs represents a separate mouse. (A) Normalized human chimerism in peripheral blood and bone marrow, shown as the percentage of human (h) CD45 1 cells. (B) Human T (CD3 1 ), B (CD19 1 ), and myeloid (M) (CD33 1 ) cells shown as percentages of the human CD45 1 population in bone marrow at 16 weeks. Erythroid chimerism (E) is shown as the percentage of human CD235a 1 cells within the CD45 2 population (mouse and human). (C) The indel fraction 4 days after editing (Pre BMT) and as measured serially after xenotransplantation. Dark blue represents the 13-nt human HPFH mutation; light blue represents all other indels. (D) Indels in specific hematopoietic lineages. Dark blue represents the 13-nt human HPFH mutation; light blue represents all other indels. (E) The most frequent indels in donor 1 CD34 1 cells before bone marrow transplantation and in the 16-week bone marrow of mouse recipients. Unique indels
Figure 3 Xenotransplantation of normal gene-edited CD34 1 cells into NBSGW mice. Peripheral blood (PB) CD34 1 cells were edited with Cas9:sgRNA-1 RNP using the Neon Transfection System and then transplanted into NBSGW mice via tail-vein injection. Donor cell controls (C) were processed in parallel, but not electroporated. Donor-cell progeny were analyzed in recipient peripheral blood at 6, 11, and 16 weeks and in bone marrow (BM) at 17 weeks after transplantation. Data are from 3 independent experiments with CD34 1 cells from different donors (red, blue, or green). Each dot in graphs represents a separate mouse. (A) Normalized human chimerism in peripheral blood and bone marrow, shown as the percentage of human (h) CD45 1 cells. (B) Human T (CD3 1 ), B (CD19 1 ), and myeloid (M) (CD33 1 ) cells shown as percentages of the human CD45 1 population in bone marrow at 16 weeks. Erythroid chimerism (E) is shown as the percentage of human CD235a 1 cells within the CD45 2 population (mouse and human). (C) The indel fraction 4 days after editing (Pre BMT) and as measured serially after xenotransplantation. Dark blue represents the 13-nt human HPFH mutation; light blue represents all other indels. (D) Indels in specific hematopoietic lineages. Dark blue represents the 13-nt human HPFH mutation; light blue represents all other indels. (E) The most frequent indels in donor 1 CD34 1 cells before bone marrow transplantation and in the 16-week bone marrow of mouse recipients. Unique indelsCC-BY-NC-ND · From the PDF
Figure 4 Consequences of on-target editing of HBG1 and HBG2 . (A) Scale diagram of the HBG1 and HBG2 genes with exons shown as rectangles and on-target Cas9:sgRNA-1 DNA cleavage sites indicated by vertical black arrows. The genes differ by a single nucleotide in exon 3 (open arrows). Primer pair If 1 Ir amplifies a region surrounding the RNP cleavage site of both genes; NGS of this PCR product identified small on-target indels. Larger deletions presumed to arise from simultaneous dsDNA breaks in HBG2 and HBG1 , with the loss of the intervening 4.9 kb (dotted line), were indicated by 2 proxy methods. ' D HBG2 ' denotes dropout of HBG2 exon 3 based on the single-nucleotide difference between HBG2 and HBG1 , determined by high-throughput sequencing of PCR products generated by a single primer pair (not shown). ' D 366 1 ' denotes a quantitative TaqMan PCR assay that detects deletions $ 366 nt upstream of the Cas9:sgRNA-1 cleavage site in HBG1 . (B) Large deletions detected by the D HBG2 and D 366 1 assays in CD34 1 cells 4 days after editing (Pre-BMT) and 17 weeks after xenotransplantation (Post-BMT). Data reflect studies from 2 different CD34 1 cell donors (blue or red dots), with each dot after bone marrow transplantation representing a single mouse. (C) Mutational analysis and %HbF in single BFU-E colonies. Each dot represents a BFU-E colony grouped by number of 4.9-kb deletions ( Del ) using the D HBG2 assay as proxy and the number of indels in the remaining BCL11A binding motifs of HBG2 , HBG1 , or the modified HBG1 fusion gene formed by deletion repair. Thus, heterozygosity for the 4.9-kb deletion leaves 3 potential remaining BCL11A-binding motifs and associated HBG coding regions, whereas homozygosity leaves only 2 such motifs. The bars represent the percentages of HbF as the
Figure 4 Consequences of on-target editing of HBG1 and HBG2 . (A) Scale diagram of the HBG1 and HBG2 genes with exons shown as rectangles and on-target Cas9:sgRNA-1 DNA cleavage sites indicated by vertical black arrows. The genes differ by a single nucleotide in exon 3 (open arrows). Primer pair If 1 Ir amplifies a region surrounding the RNP cleavage site of both genes; NGS of this PCR product identified small on-target indels. Larger deletions presumed to arise from simultaneous dsDNA breaks in HBG2 and HBG1 , with the loss of the intervening 4.9 kb (dotted line), were indicated by 2 proxy methods. ' D HBG2 ' denotes dropout of HBG2 exon 3 based on the single-nucleotide difference between HBG2 and HBG1 , determined by high-throughput sequencing of PCR products generated by a single primer pair (not shown). ' D 366 1 ' denotes a quantitative TaqMan PCR assay that detects deletions $ 366 nt upstream of the Cas9:sgRNA-1 cleavage site in HBG1 . (B) Large deletions detected by the D HBG2 and D 366 1 assays in CD34 1 cells 4 days after editing (Pre-BMT) and 17 weeks after xenotransplantation (Post-BMT). Data reflect studies from 2 different CD34 1 cell donors (blue or red dots), with each dot after bone marrow transplantation representing a single mouse. (C) Mutational analysis and %HbF in single BFU-E colonies. Each dot represents a BFU-E colony grouped by number of 4.9-kb deletions ( Del ) using the D HBG2 assay as proxy and the number of indels in the remaining BCL11A binding motifs of HBG2 , HBG1 , or the modified HBG1 fusion gene formed by deletion repair. Thus, heterozygosity for the 4.9-kb deletion leaves 3 potential remaining BCL11A-binding motifs and associated HBG coding regions, whereas homozygosity leaves only 2 such motifs. The bars represent the percentages of HbF as theCC-BY-NC-ND · From the PDF
Figure 5 No off-target mutations are detected by a sensitive assay in CD34 1 HSPCs after editing at the g -globin gene promoters. Purified genomic DNA from normal CD34 1 cell -derived erythroblasts was analyzed by the CIRCLE-seq method for defining Cas9 genome-wide activity in vitro. The left panel shows the 25 most frequent candidate off-target sites for Cas9:sgRNA-1 RNP identified by CIRCLE-seq analysis on purified genomic DNA. The on-target sites including sgRNA and PAM sequences are shown at the top. Off-target sites are ordered by CIRCLE-seq read count, with matches to the intended target site shown as dots and mismatches shown as colored nucleotides. The right panel shows the indel frequencies at candidate off-target sites validated by targeted high-throughput sequencing of CD34 1 HSPCs edited with Cas9:sgRNA-1 RNP using the Neon Transfection System (blue squares) and control nonedited CD34 1 cells (red circles). The threshold of detection for NGS is ; 0.01% to 0.1%.
Figure 5 No off-target mutations are detected by a sensitive assay in CD34 1 HSPCs after editing at the g -globin gene promoters. Purified genomic DNA from normal CD34 1 cell -derived erythroblasts was analyzed by the CIRCLE-seq method for defining Cas9 genome-wide activity in vitro. The left panel shows the 25 most frequent candidate off-target sites for Cas9:sgRNA-1 RNP identified by CIRCLE-seq analysis on purified genomic DNA. The on-target sites including sgRNA and PAM sequences are shown at the top. Off-target sites are ordered by CIRCLE-seq read count, with matches to the intended target site shown as dots and mismatches shown as colored nucleotides. The right panel shows the indel frequencies at candidate off-target sites validated by targeted high-throughput sequencing of CD34 1 HSPCs edited with Cas9:sgRNA-1 RNP using the Neon Transfection System (blue squares) and control nonedited CD34 1 cells (red circles). The threshold of detection for NGS is ; 0.01% to 0.1%.CC-BY-NC-ND · From the PDF
Figure 4 (continued) means 6 SDs. ** P , .01, *** P , .001, **** P , .0001 (by unpaired Student t test). (D) Inversions resulting from simultaneous editing of HBG2 and HBG1 target sites were characterized by PCR analysis using the indicated primer pairs. The agarose gel image shows PCR products from the bulk-edited HUDEP-2 (H2) erythroid cell line and CD34 1 cells. ns, not significant.
Figure 4 (continued) means 6 SDs. ** P , .01, *** P , .001, **** P , .0001 (by unpaired Student t test). (D) Inversions resulting from simultaneous editing of HBG2 and HBG1 target sites were characterized by PCR analysis using the indicated primer pairs. The agarose gel image shows PCR products from the bulk-edited HUDEP-2 (H2) erythroid cell line and CD34 1 cells. ns, not significant.CC-BY-NC-ND · From the PDF
Figure 6 HBG1 and HBG2 promoters in CD34 1 HSPCs from individuals with SCD induces HbF expression in erythroid progeny generated after
Figure 6 HBG1 and HBG2 promoters in CD34 1 HSPCs from individuals with SCD induces HbF expression in erythroid progeny generated afterCC-BY-NC-ND · From the PDF
Figure 7 Improved genome editing of the HBG1 and HBG2 promoters in HSCs by Cas9-3xNLS. (A) Schematic overview of Cas9-2xNLS and Cas9-3xNLS proteins showing locations of nuclear localization signals. (B) Normal human CD34 1 cells from 2 different donors (#1 and #2 represented by blue and red dots, respectively) were edited using 4 different delivery methods with the Lonza 4D-Nucleofector platform (x-axis) with RNPs composed of sgRNA-1 and either Cas9-3xNLS (red bar) or Cas9-2xNLS (blue bar), then cultured in CD34 1 cell maintenance medium (supplemental Table 2). Nonedited donor-cell controls (C) were processed in parallel, but not electroporated. Indels were analyzed at day 3 by NGS. (C-F) Normal CD34 1 cells from 2 different donors were edited with the Lonza 4D-Nucleofector (EO-100 program) and RNP composed of sgRNA-1:Cas9-3xNL and then transplanted into NBSGW mice. (C) Normalized chimerism of human CD45 1 donor cells in recipient bone marrow at 16 weeks after xenotransplantation. (D) Chimerism for different human lineages, labeled as in Figure 3B. (E) Frequencies of small indels detected by TIDE assay and large (4.9 kb) deletions detected by the D 366 1 assay (Figure 4A) in donor CD34 1 cells 5 days after editing (Pre) and 16 weeks after bone marrow transplantation. The 13-nt HPFH mutation is indicated in dark blue; all other mutations are represented by light blue. (F) Donor CD34 1 cells were purified from recipient bone marrow and grown in culture for 18 days under erythroid differentiation conditions. The bar chart shows %HbF as determined by ion-exchange HPLC. Each dot represents a biological replicate experiment with 2 different CD34 1 cell donors (blue and red). ** P , .01 and **** P , .0001 (unpaired Student t test).
Figure 7 Improved genome editing of the HBG1 and HBG2 promoters in HSCs by Cas9-3xNLS. (A) Schematic overview of Cas9-2xNLS and Cas9-3xNLS proteins showing locations of nuclear localization signals. (B) Normal human CD34 1 cells from 2 different donors (#1 and #2 represented by blue and red dots, respectively) were edited using 4 different delivery methods with the Lonza 4D-Nucleofector platform (x-axis) with RNPs composed of sgRNA-1 and either Cas9-3xNLS (red bar) or Cas9-2xNLS (blue bar), then cultured in CD34 1 cell maintenance medium (supplemental Table 2). Nonedited donor-cell controls (C) were processed in parallel, but not electroporated. Indels were analyzed at day 3 by NGS. (C-F) Normal CD34 1 cells from 2 different donors were edited with the Lonza 4D-Nucleofector (EO-100 program) and RNP composed of sgRNA-1:Cas9-3xNL and then transplanted into NBSGW mice. (C) Normalized chimerism of human CD45 1 donor cells in recipient bone marrow at 16 weeks after xenotransplantation. (D) Chimerism for different human lineages, labeled as in Figure 3B. (E) Frequencies of small indels detected by TIDE assay and large (4.9 kb) deletions detected by the D 366 1 assay (Figure 4A) in donor CD34 1 cells 5 days after editing (Pre) and 16 weeks after bone marrow transplantation. The 13-nt HPFH mutation is indicated in dark blue; all other mutations are represented by light blue. (F) Donor CD34 1 cells were purified from recipient bone marrow and grown in culture for 18 days under erythroid differentiation conditions. The bar chart shows %HbF as determined by ion-exchange HPLC. Each dot represents a biological replicate experiment with 2 different CD34 1 cell donors (blue and red). ** P , .01 and **** P , .0001 (unpaired Student t test).CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Cited by

See all 177

Metadata

Authors
Métais, J.-Y., Doerfler, P. A., Mayuranathan, T., Bauer, D. E., Fowler, S. C., Hsieh, M. M., Katta, V., Keriwala, S., Lazzarotto, C. R., Luk, K., Neel, M. D., Perry, S. S., Peters, S. T., Porter, S. N., Ryu, B. Y., Sharma, A., Shea, D., Tisdale, J. F., Uchida, N., Wolfe, S. A., Woodard, K. J., Wu, Y., Yao, Y., Zeng, J., Pruett-Miller, S., Tsai, S. Q., & Weiss, M. J.
Affiliations
  • St. Jude Children's Research Hospital (US)
  • Broad Institute (US)
  • National Heart, Lung, and Blood Institute (US)
  • Department of Hematology, St. Jude Children’s Research Hospital, Memphis, TN;
  • University of Massachusetts Chan Medical School (US)
  • Division of Orthopedics,
  • Flow Cytometry and Cell Sorting Shared Resource,
  • Department of Cell and Molecular Biology, and
  • Boston Children's Hospital (US)
Venue
Blood Advances
Published
2019-11-06
Volume
3
Issue
21
Pages
3379-3392
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W2983573843
Cited by
177
References
56
Citations by year
2026: 17 · 2025: 20 · 2024: 24 · 2023: 30 · 2022: 32 · 2021: 34 · 2020: 18
FWCI
11.51
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Blood Advances (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship@UMassChan (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Doris Duke Charitable Foundation (2017093)
  • Assisi Foundation of Memphis
  • St. Jude Children's Research Hospital (CA21765)
  • American Lebanese Syrian Associated Charities (CA 21765)
  • National Institutes of Health (CA21765))
  • National Heart, Lung, and Blood Institute (P01HL053749, HL053749, U01HL145793)
  • National Cancer Institute (CA21765, P 30CA 21765, P30CA021765)
  • National Institute of General Medical Sciences (R01GM115911, CA21765)
  • National Institute of Allergy and Infectious Diseases (R01AI117839, U01AI157189)
  • National Institute of Biomedical Imaging and Bioengineering (U01EB029373)
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
genome editing, fetal hemoglobin induction, HBG1, HBG2, sickle cell disease, beta-thalassemia, CRISPR/Cas9, BCL11A, hematopoietic stem and progenitor cells, xenotransplantation, CIRCLE-seq, off-target mutations, nuclear localization signal, hemoglobinopathies
MeSH terms
Gene Editing, RNA, Guide, CRISPR-Cas Systems, Anemia, Sickle Cell, Animals, Base Sequence, Disease Models, Animal, Erythropoiesis, Fetal Hemoglobin, Gene Expression Regulation, Hematopoietic Stem Cells, Hemoglobinopathies, Humans, Models, Biological, Mutation, Promoter Regions, Genetic, Immunophenotyping, Sequence Deletion, RNA, Guide, Kinetoplastida, Hematopoietic Stem Cell Transplantation, Gene Targeting, Mice, gamma-Globins, CRISPR-Cas Systems, Heterografts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genome editing of HBG1 and HBG2 to induce fetal hemoglobin. https://app.cochat.ai/papers/10.1182/bloodadvances.2019000820
The paper
Métais, J.-Y., Doerfler, P. A., Mayuranathan, T., Bauer, D. E., Fowler, S. C., Hsieh, M. M., Katta, V., Keriwala, S., Lazzarotto, C. R., Luk, K., Neel, M. D., Perry, S. S., Peters, S. T., Porter, S. N., Ryu, B. Y., Sharma, A., Shea, D., Tisdale, J. F., Uchida, N., . . . Weiss, M. J. (2019). Genome editing of HBG1 and HBG2 to induce fetal hemoglobin. Blood Advances. https://doi.org/10.1182/bloodadvances.2019000820

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.